Technology ID
TAB-4526
Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression
E-Numbers
E-199-2018-0
Lead Inventor
Li, Lina
Co-Inventors
Kotin, Robert (Carbon Biosciences)
Applications
Therapeutics
Research Materials
Development Stages
Pre-Clinical (in vitro)
Research Products
Plasmids/Vectors
Lead IC
NHLBI
This technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins to produce ceDNA.
Commercial Applications
Spodoptera frugiperda (Sf9) cells were developed to produce recombinant adeno-associated virus. This technology can be used for the large-scale production of recombinant adeno-associated virus (rAAV), a critical component in gene therapy, by employing Spodoptera frugiperda (Sf9) cells for efficient and controlled replication and packaging of the virus.
Competitive Advantages
The simplified process has manufacturing advantages compared to the co-infection systems (using either 2 or 3 baculoviruses), with higher production and improved yields.
Licensing Contact: